Farmer 2017.

Study characteristics
Methods	Study design: multi centre, open‐label, parallel randomised controlled trial in the UK Duration: 52 weeks Setting: secondary care, primary care, community services
Participants	Population: 166 adults recruited from respiratory hospital outpatient clinics and primary care Baseline characteristics: male: 62% IG and 61% CG, mean age: 69.8 IG and 69.8 CG, median number of COPD medication: 5 IG and 5 CG, FEV1 (% predicted): 47.4 IG and 50.1 CG, ex‐smoker: 79% IG and 76% CG, current smoker: 20.9% IG and 23.3% CG, severe or very severe COPD: 63% IG and 59% CG Inclusion criteria: COPD diagnosis, FEV1 post bronchodilation < 80% and predicted FEV/FVC ratio < 0.70, smoking > 10 pack years, MRC dyspnoea >= 2, registered with a GP and had a COPD exacerbation in the last 12 months or referred to PR Exclusion criteria: other significant lung disease, chronic heart failure, life expectancy < 3 months, cognitive impairment, no Internet‐enabled mobile phone network
Interventions	Measurements were taken at baseline and 12 months follow‐up. Treatment arms: Internet‐linked, tablet computer‐based system of monitoring and self‐management support (EDGE) Standard care included the same information as the intervention group, but were not given any equipment for monitoring symptoms
Outcomes	Quality of life (SGRQ, ED‐5D‐5L) Hospital utilisation (people requiring admissions) Anxiety and depression (SCL‐10) Exacerbations Adverse and severe adverse events
Notes	Funding: Wellcome Trust and Department of Health Other identifiers: ISRCTN40367841
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer programme (Sortiton V1.2) was used to randomise participants.
Allocation concealment (selection bias)	Unclear risk	It is unclear whether the allocation was concealed or not.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Neither the study investigators or patients were blinded.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open‐label study
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was similar in each treatment group, with 15.5% lost to follow‐up in the intervention arm and 14.3% lost to follow‐up from the control arm.
Selective reporting (reporting bias)	Low risk	Outcomes were reported as planned.
Other bias	Low risk	None detected.